Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR. Pavlidis N, et al. Among authors: punt c. Cancer Chemother Pharmacol. 2000;46(2):167-71. doi: 10.1007/s002800000134. Cancer Chemother Pharmacol. 2000. PMID: 10972487 Clinical Trial.
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
van Kesteren C, Mathôt RA, Raymond E, Armand JP, Fumoleau P, Punt C, Ravic M, Wanders J, Beijnen JH, Schellens JH; Early Clinical Studies Group of the EORTC and NDDO Oncology. van Kesteren C, et al. Among authors: punt c. Br J Clin Pharmacol. 2002 Nov;54(5):463-71. doi: 10.1046/j.1365-2125.2002.01684.x. Br J Clin Pharmacol. 2002. PMID: 12445024 Free PMC article. Clinical Trial.
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Van Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH; Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer. Van Kesteren Ch, et al. Among authors: punt c. J Clin Oncol. 2002 Oct 1;20(19):4065-73. doi: 10.1200/JCO.2002.01.005. J Clin Oncol. 2002. PMID: 12351604
Population pharmacokinetics of the novel anticancer agent KRN7000.
Crul M, Mathôt RA, Giaccone G, Punt CA, Rosing H, Hillebrand MX, Ando Y, Nishi N, Tanaka H, Schellens JM, Beijnen JH. Crul M, et al. Cancer Chemother Pharmacol. 2002 Apr;49(4):287-93. doi: 10.1007/s00280-001-0413-3. Epub 2002 Jan 24. Cancer Chemother Pharmacol. 2002. PMID: 11914907 Clinical Trial.
Prognostic value of radiologic and pathological response in colorectal cancer liver metastases upon systemic induction treatment: subgroup analysis of the CAIRO5 trial.
Bond MJG, Mijnals C, Bolhuis K, van Amerongen MJ, Engelbrecht MRW, Hermans JJ, van Lienden KP, May AM, Swijnenburg RJ, Punt CJA. Bond MJG, et al. Among authors: punt cja. ESMO Open. 2024 Dec;9(12):104075. doi: 10.1016/j.esmoop.2024.104075. Epub 2024 Dec 11. ESMO Open. 2024. PMID: 39667310 Free PMC article. Clinical Trial.
Pembrolizumab Versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study.
André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, Fouchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zuo Y, Fogelman D, Adelberg D, Diaz LA Jr. André T, et al. Among authors: punt cja. Ann Oncol. 2024 Dec 2:S0923-7534(24)04949-4. doi: 10.1016/j.annonc.2024.11.012. Online ahead of print. Ann Oncol. 2024. PMID: 39631622
Development and external evaluation of a self-learning auto-segmentation model for Colorectal Cancer Liver Metastases Assessment (COALA).
Bereska JI, Zeeuw M, Wagenaar L, Jenssen HB, Wesdorp NJ, van der Meulen D, Bereska LF, Gavves E, Janssen BV, Besselink MG, Marquering HA, van Waesberghe JTM, Aghayan DL, Pelanis E, van den Bergh J, Nota IIM, Moos S, Kemmerich G, Syversveen T, Kolrud FK, Huiskens J, Swijnenburg RJ, Punt CJA, Stoker J, Edwin B, Fretland ÅA, Kazemier G, Verpalen IM; Pancreatobiliary and Hepatic Artificial Intelligence Research (PHAIR) consortium; Dutch Colorectal Cancer Group Liver Expert Panel. Bereska JI, et al. Among authors: punt cja. Insights Imaging. 2024 Nov 22;15(1):279. doi: 10.1186/s13244-024-01820-7. Insights Imaging. 2024. PMID: 39576456 Free PMC article.
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.
Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, Rijken AM, Verhoef C, de Wilt JHW, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MRW, van Lienden KP, Hermans JJ, Molenaar IQ, Grünhagen DJ, de Valk B, Haberkorn BCM, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, Komurcu A, May AM, Swijnenburg RJ, Punt CJA; Dutch Colorectal Cancer Group. Bond MJG, et al. Among authors: punt cja. JAMA Oncol. 2024 Nov 21:e245174. doi: 10.1001/jamaoncol.2024.5174. Online ahead of print. JAMA Oncol. 2024. PMID: 39570583
Cancer treatment monitoring using cell-free DNA fragmentomes.
van 't Erve I, Alipanahi B, Lumbard K, Skidmore ZL, Rinaldi L, Millberg LK, Carey J, Chesnick B, Cristiano S, Portwood C, Wu T, Peters E, Bolhuis K, Punt CJA, Tom J, Bach PB, Dracopoli NC, Meijer GA, Scharpf RB, Velculescu VE, Fijneman RJA, Leal A. van 't Erve I, et al. Among authors: punt cja. Nat Commun. 2024 Oct 21;15(1):8801. doi: 10.1038/s41467-024-53017-7. Nat Commun. 2024. PMID: 39433569 Free PMC article.
532 results